Skip to main content

Marina Buys Novosom Delivery Technology for $5M in Stock

Premium

Marina Biotech, formerly MDRNA, said this week that it has acquired certain drug-delivery intellectual property from Novosom for roughly $5 million in stock.

Specifically, Marina has picked up the rights to Novosom's Smarticle technology, a liposome-based delivery vehicle applicable for both systemic and local siRNA administration, the company said. It is covered by 42 issued or allowed patents and 31 pending patent applications worldwide.

Additional terms of the transaction were not disclosed.

"We believe that this technology and intellectual property estate, resulting from years of hard work and diligent IP prosecution on the part of Novosom, is a significant addition to our existing RNA delivery platforms and … IP estate," Marina President and CEO Michael French said in a statement.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.